Liquid biopsies are more representative than tissue biopsies for BRCA1/2 mutations, with BRCA2 mutations occurring at double the incidence of BRCA1 mutations, indicating that BRCA1/2 mutations may be readily detected in CRC patients' blood samples. This evidence concerns the gene BRCA2 and colorectal carcinoma.